#Argentine #vaccine #covid #stopped #due #lack #funds
Tuesday, April 9, 2024 – Nationals
This is ArgenVac, the second vaccine against coronavirus created in the country, which had three years of research and joint work between the National University of La Plata (UNLP), the University of Buenos Aires (UBA), Conicet and the biotechnology company from Mar del Plata Gijón.
Listen/Download the report from Radio Estación Sur de La Plata, Buenos Aires.
Due to lack of funds, two Argentine public universities slowed the progress of the Covid-19 vaccine that was being developed in the country and was ready to enter its final stages.
It’s about the ArgenVacthe second coronavirus vaccine created in the country, had three years of research and joint work between the National University of La Plata (UNLP), the Buenos Aires’ University (UBA), the Conicet and the Mar del Plata biotechnology company Gijon.
William Docenaresearcher of Institute of Immunological and Pathophysiological Studiesfrom the Faculty of Exact Sciences of the UNLP and CONICET, admitted that the research could have ended earlier but “With all the financing problems that there were, it became very difficult to move forward”.
“That delayed it, but that’s why the important thing is that we have arrived.”he added in dialogue with Radio Station South and reproduced by FARCO Informational.
The Argentine vaccine had completed the stage in which the vaccine was tested on experimental animals. “It is the first step that must be taken before going to volunteers, to humans”clarified Docena, who also pointed out that the ArgenVac had been successfully tested on mice.
However, human testing and approval of National Administration of Drugs, Foods and Medical Technology (ANMAT) will not be carried out due to lack of funds. “We decided to end it because we ran out of funding. We can do everything that involves publications but it is very difficult to move forward.“, lament.
The figure to advance the development of the vaccine is 500 thousand dollars. ““That money is nowhere to be found.”stated the researcher, who knows the details of the costs because the other Arvac vaccine managed to finish the preclinical and clinical phase.
“That is why we know the scale of amounts needed. But we cannot go ahead, not even with tests on experimental animals. So much less can we do it in a clinical trial in humans because there is no availability of funds”, he insisted.
